Yasmin Karimi

12PUBLICATIONS
88CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursImmunology not elsewhere classifiedRadiation and matter
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 05, 2026
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

|Jul 29, 2025
Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).

Jonathan Weiss, Shannon A Carty, Yasmin H Karimi

|Jul 15, 2025
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Taylor R Brooks, Emily C Zabor, Yohanna B Bedelu

|Jun 09, 2025
Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma.

Meng-Hsuan Lin, Jonathan Weiss, Tycel J Phillips

|Jan 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.

Joshua D Brody, Judit Jørgensen, David Belada

|Aug 27, 2024
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series.

Narendranath Epperla, Adam S Zayac, Daniel J Landsburg

Pageof 2

Frequent Collaborators

4 joint publications

Joshua D Brody

3 joint publications

Stephen D Smith

3 joint publications

David Bond

3 joint publications

Emily C Ayers